(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 3.67% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.15%.
Amgen's revenue in 2026 is $38,095,000,000.On average, 36 Wall Street analysts forecast AMGN's revenue for 2026 to be $21,453,359,222,410, with the lowest AMGN revenue forecast at $20,015,278,089,110, and the highest AMGN revenue forecast at $22,364,324,150,835. On average, 36 Wall Street analysts forecast AMGN's revenue for 2027 to be $22,210,244,029,410, with the lowest AMGN revenue forecast at $20,510,497,005,690, and the highest AMGN revenue forecast at $25,001,527,071,225.
In 2028, AMGN is forecast to generate $22,941,719,132,175 in revenue, with the lowest revenue forecast at $20,190,442,858,730 and the highest revenue forecast at $26,812,103,655,970.